Clinically significant portal hypertension is associated with an increased risk of developing
gastro-oesophageal varices and hepatic decompensation. Hepatic venous pressure …

Noninvasive diagnostics for portal hypertension include imaging and functional tests, as well
as blood-based biomarkers, and capture different features of the portal hypertensive …

Abstract Background & Aims Liver fibrosis assessed by liver biopsy is predictive of clinical
liver events in patients with nonalcoholic fatty liver disease (NAFLD). Magnetic resonance …

Abstract Lysyl oxidase-like 2 (LOXL2) is an extracellular copper-dependent enzyme that
plays a central role in fibrosis by catalyzing the crosslinking and deposition of collagen …

Clinically significant portal hypertension (CSPH) is associated with an incremental risk of
esophageal varices and overt clinical decompensations. However, hepatic venous pressure …

Objectives Portal hypertension (PH) is associated with complications such as ascites and
esophageal varices and is typically diagnosed through invasive hepatic venous pressure …

Nonalcoholic fatty liver disease (NAFLD) advanced to cirrhosis is often complicated by
clinically significant portal hypertension, which is primarily caused by increased intrahepatic …

All patients with liver cirrhosis and portal hypertension should be stratified by risk groups to
individualize different therapeutic strategies to increase the effectiveness of treatment. In this …

Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide
and has become the second most common indication for liver transplantation as it may …

Background MR elastography can determine organ‐related stiffness, which reflects the
degree of fibrosis. Liver stiffness increases in cirrhosis, and stiffness increases further post …